液体活检作为常规采集的儿童肿瘤患者样本拷贝数畸变分析补充检测的可行性
该研究对128例不同实体瘤儿童患者的配对血浆游离DNA与组织DNA行浅层全基因组测序拷贝数畸变分析,发现两者总体一致性良好,不一致主因为游离DNA样本质量低;在神经母细胞瘤中MYCN扩增检测无误判。作者认为质量合格的液体活检在未来前瞻性研究中可作为组织活检拷贝数分析的补充检测。
要点
- 128例儿童实体瘤患者配对血浆cfDNA与组织DNA的拷贝数畸变分析总体一致性良好。
- 拷贝数不一致的主要原因是cfDNA样本质量低,即cfDNA(<700 bp)与高分子量DNA(>700 bp)的比值。
- 神经母细胞瘤样本中MYCN扩增检测未发现假阳性或假阴性。
核心结论
- 在未来前瞻性研究中,质量合格的液体活检拷贝数畸变分析可作为组织活检拷贝数分析的补充检测,因为cfDNA或组织DNA均可能含有对方无法检出的拷贝数畸变。
研究设计与样本
- 回顾性拷贝数畸变分析,采用浅层全基因组测序检测配对血浆游离DNA与组织DNA样本。
- 样本来自常规采集的儿童肿瘤患者,共128例,涵盖骨肉瘤、尤因肉瘤、横纹肌肉瘤、Wilms瘤、脑肿瘤和神经母细胞瘤等不同肿瘤类型。
主要发现
- 总体而言,组织DNA与cfDNA的拷贝数畸变之间观察到良好一致性。
- 拷贝数畸变不一致的主要原因是cfDNA样本质量低,即cfDNA(<700 bp)与高分子量DNA(>700 bp)的比值。
- 观察到cfDNA中存在而组织DNA中不存在的拷贝数畸变,反之亦然。
- 在神经母细胞瘤样本中,预后标志物MYCN扩增检测未发现假阳性或假阴性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Paediatric tumours are often characterised by the presence of recurrent DNA copy number alterations (CNAs). These DNA copy number profiles, obtained from a tissue biopsy, can aid in the correct prognostic classification and therapeutic stratification of several paediatric cancer entities (e.g. MYCN amplification in neuroblastoma) and are part of the routine diagnostic practice. Liquid biopsies (LQBs) offer a potentially safer alternative for such invasive tumour tissue biopsies and can provide deeper insight into tumour heterogeneity. PROCEDURE: The robustness and reliability of LQB CNA analyses was evaluated. We performed retrospective CNA profiling using shallow whole-genome sequencing (sWGS) on paired plasma circulating cell-free DNA (cfDNA) and tissue DNA samples from routinely collected samples from paediatric patients (n = 128) representing different tumour entities, including osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, Wilms tumour, brain tumours and neuroblastoma. RESULTS: Overall, we observed a good concordance between CNAs in tissue DNA and cfDNA. The main cause of CNA discordance was found to be low cfDNA sample quality (i.e. the ratio of cfDNA (<700 bp) and high molecular weight DNA (>700 bp)). Furthermore, CNAs were observed that were present in cfDNA and not in tissue DNA, or vice-versa. In neuroblastoma samples, no false-positives or false-negatives were identified for the detection of the prognostic marker MYCN amplification. CONCLUSION: In future prospective studies, CNA analysis on LQBs that are of sufficient quality can serve as a complementary assay for CNA analysis on tissue biopsies, as either cfDNA or tissue DNA can contain CNAs that cannot be identified in the other biomaterial.
引用
- Van Paemel R, Vandeputte C, Raman L, et al. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. Eur J Cancer. 2021. PMID: 34794856. doi:10.1016/j.ejca.2021.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。